A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Public ClinicalTrials.gov record NCT04188548. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.
Study identification
- NCT ID
- NCT04188548
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 379 participants
Conditions and interventions
Interventions
- LY3484356 Drug
- Abemaciclib Drug
- Everolimus Drug
- Alpelisib Drug
- Trastuzumab Drug
- Aromatase Inhibitor (AI) Drug
- Pertuzumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 10, 2019 (Actual)
- Primary completion
- Jun 29, 2020 (Actual)
- Completion
- Dec 2027 (Estimated)
- Last update posted
- Jun 22, 2026
2019 – 2027
United States locations
- U.S. sites
- 42
- U.S. states
- 23
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Mayo Clinic in Arizona - Phoenix | Phoenix | Arizona | 85054 | — |
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| Beverly Hills Cancer Center | Beverly Hills | California | 90211 | — |
| University of California, Irvine | Orange | California | 92868 | — |
| UCSF Medical Center at Mission Bay | San Francisco | California | 94158 | — |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224 | — |
| Lake Nona DDU | Orlando | Florida | 32827 | — |
| Winship Cancer Center Emory University | Atlanta | Georgia | 30322 | — |
| Community Cancer Center North | Indianapolis | Indiana | 46250 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Minnesota Oncology/Hematology PA | Minneapolis | Minnesota | 55404 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Memorial Sloan Kettering - Bergen | Montvale | New Jersey | 07645 | — |
| Memorial Sloan Kettering Cancer Center | Commack | New York | 11725 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Wilmot Cancer Institute | Rochester | New York | 14642 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| Ohio State University Medical Center | Columbus | Ohio | 43210 | — |
| University of Oklahoma Health Sciences Center, Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Asante Rogue Regional Medical Center | Medford | Oregon | 97504 | — |
| UPMC Hillman Cancer Center Harrisburg | Harrisburg | Pennsylvania | 17109 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Vanderbilt Health One Hundred Oaks | Nashville | Tennessee | 37067 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology Nashville | Nashville | Tennessee | 37203 | — |
| UT Southwestern Med Center | Dallas | Texas | 75390-9179 | — |
| Texas Oncology-Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 77380 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
| South Texas Accelerated Research Therapeutics (START) | San Antonio | Texas | 78229-3307 | — |
| Minnesota Oncology/Hematology PA | The Woodlands | Texas | 77380 | — |
| Oncology and Hematology Associates of Southwest Virginia Inc | The Woodlands | Texas | 77380 | — |
| Texas Oncology - San Antonio Medical Center | The Woodlands | Texas | 77380 | — |
| US Oncology | The Woodlands | Texas | 77380 | — |
| USO-Rocky Mountain Cancer Center | The Woodlands | Texas | 77380 | — |
| Texas Oncology - Tyler | Tyler | Texas | 75702 | — |
| The University of Vermont Medical Center Inc. | Burlington | Vermont | 05401 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04188548, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 22, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04188548 live on ClinicalTrials.gov.